Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 10Lymphoma 7Lymphoma, Follicular 5Lymphoma, Non-Hodgkin 4Lymphoma, T-Cell, Cutaneous 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 73fludarabine phosphate 42Filgrastim 38Peripheral Blood Stem Cell Transplantation 35Radiotherapy 33Cyclosporine 32Busulfan 32Mycophenolic Acid 30Etoposide 29Antilymphocyte Serum 28Whole-Body Irradiation 26Methotrexate 25Melphalan 21Methylprednisolone 20Rituximab 19Vincristine 17Tacrolimus 17Cytarabine 17Cord Blood Stem Cell Transplantation 17Doxorubicin 14Prednisone 13Thiotepa 10Granulocyte Colony-Stimulating Factor 9Leucovorin 7Carboplatin 7fludarabine 6aldesleukin 6sargramostim 5Sirolimus 5Psychiatric Rehabilitation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × durvalumab × Lymphoid × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡